Market Cap 35.99M
Revenue (ttm) 1.41M
Net Income (ttm) -62.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,426.95%
Debt to Equity Ratio -0.38
Volume 2,625,900
Avg Vol 7,937,352
Day's Range N/A - N/A
Shares Out 64.11M
Stochastic %K 18%
Beta 0.17
Analysts Sell
Price Target $6.10

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 619 3990
Address:
111 S. Wood Avenue, Unit #100, Iselin, United States
mountainman5050
mountainman5050 Jan. 14 at 10:27 PM
$OTLK Hopefully The OTLK plan will benefit longs for there commitment . 👍😉✅
1 · Reply
Aawilliam2003
Aawilliam2003 Jan. 14 at 10:21 PM
$OTLK I think it’s the end of the road. Compounded avastin is doing just fine, thank you very much. Can’t find a single ophthalmologist who thinks Lyvenata is really needed in the market. And the FDA apparently agrees now. And let’s be honest- nobody gives a rats ass about Europe. It’s where drugs go to die
1 · Reply
Alder77
Alder77 Jan. 14 at 9:08 PM
$OTLK Closed at the lows of the day and decreasing volume. We'll likely test the 52W low in the next few days, hoping it holds. As mentioned, if management doesn't release a statement or future plans on what to do, we'll only continue to decline.
0 · Reply
donkr
donkr Jan. 14 at 8:43 PM
$OTLK I've finalized my position at 2000 shares at $1.29. I've been growing that position since October 2024 and have slowly recently now started to diversify which was my goal with the profits from here but plans change. Whatever happens with those 2000 shares happens I simply know too much about this company to sit on the sidelines with no vested interest at this point. No communication for this length is historically unusual for otlk though, my bet would be lawyer driven silence during clarifying discussions with FDA despite the public perception shitstorm but who knows.
0 · Reply
garygb
garygb Jan. 14 at 7:25 PM
$OTLK This thing must have a bottom. Right?
3 · Reply
adayxs
adayxs Jan. 14 at 7:23 PM
$OTLK Alfadogg is spot on with this. 1). BP & their FDA puppets will never allow a disruptor like OTLK to threaten major profit streams. 2). LYT must obviously pose a threat to them.
1 · Reply
adayxs
adayxs Jan. 14 at 7:12 PM
$OTLK This stands in Outlooks favor as the winds are changing. BP has never faced a cliff this big before. Let us hope management has some good sense. I like the sound of a good milestone deal. Jahr and Cantrell are very experienced at this. https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
1 · Reply
Alfadogg
Alfadogg Jan. 14 at 7:03 PM
$OTLK I think it is safe to say that we all DAMN WELL KNOW that BP is not allowing the FDA to approve LYT. Perhaps OTLK thought a “Class 1” resubmission would pass muster, as most do. Perhaps other “arrangements” were in play. But we should all be aware of four things now, seemingly without question: 1). BP & their FDA puppets will never allow a disruptor like OTLK to threaten major profit streams. 2). LYT must obviously pose a threat to them. 3). Cencora is evidently NOT going to use its muscle to overpower BP in this case 4). It appears that the only paths foward are: licensing, partnership, buyout, or belly up. Imho.
1 · Reply
FrancX
FrancX Jan. 14 at 7:03 PM
$OTLK OMG is like an horror film…
1 · Reply
Ihuarraqax123
Ihuarraqax123 Jan. 14 at 7:00 PM
$OTLK what a mess ...
0 · Reply
Latest News on OTLK
Outlook Therapeutics Announces New Employment Inducement Grants

Dec 26, 2025, 5:00 PM EST - 19 days ago

Outlook Therapeutics Announces New Employment Inducement Grants


Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 29, 2025, 8:45 AM EDT - 3 months ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA


Outlook Therapeutics Requests Type A Meeting with FDA

Sep 2, 2025, 8:35 AM EDT - 4 months ago

Outlook Therapeutics Requests Type A Meeting with FDA


FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Aug 28, 2025, 11:15 AM EDT - 4 months ago

FDA Rejects Outlook Therapeutics Eye Drug For Second Time


Top 3 Health Care Stocks That Could Blast Off This Month

Jan 6, 2025, 7:19 AM EST - 1 year ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT


Outlook Therapeutics® Streamlines Operations

Dec 13, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Streamlines Operations


mountainman5050
mountainman5050 Jan. 14 at 10:27 PM
$OTLK Hopefully The OTLK plan will benefit longs for there commitment . 👍😉✅
1 · Reply
Aawilliam2003
Aawilliam2003 Jan. 14 at 10:21 PM
$OTLK I think it’s the end of the road. Compounded avastin is doing just fine, thank you very much. Can’t find a single ophthalmologist who thinks Lyvenata is really needed in the market. And the FDA apparently agrees now. And let’s be honest- nobody gives a rats ass about Europe. It’s where drugs go to die
1 · Reply
Alder77
Alder77 Jan. 14 at 9:08 PM
$OTLK Closed at the lows of the day and decreasing volume. We'll likely test the 52W low in the next few days, hoping it holds. As mentioned, if management doesn't release a statement or future plans on what to do, we'll only continue to decline.
0 · Reply
donkr
donkr Jan. 14 at 8:43 PM
$OTLK I've finalized my position at 2000 shares at $1.29. I've been growing that position since October 2024 and have slowly recently now started to diversify which was my goal with the profits from here but plans change. Whatever happens with those 2000 shares happens I simply know too much about this company to sit on the sidelines with no vested interest at this point. No communication for this length is historically unusual for otlk though, my bet would be lawyer driven silence during clarifying discussions with FDA despite the public perception shitstorm but who knows.
0 · Reply
garygb
garygb Jan. 14 at 7:25 PM
$OTLK This thing must have a bottom. Right?
3 · Reply
adayxs
adayxs Jan. 14 at 7:23 PM
$OTLK Alfadogg is spot on with this. 1). BP & their FDA puppets will never allow a disruptor like OTLK to threaten major profit streams. 2). LYT must obviously pose a threat to them.
1 · Reply
adayxs
adayxs Jan. 14 at 7:12 PM
$OTLK This stands in Outlooks favor as the winds are changing. BP has never faced a cliff this big before. Let us hope management has some good sense. I like the sound of a good milestone deal. Jahr and Cantrell are very experienced at this. https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
1 · Reply
Alfadogg
Alfadogg Jan. 14 at 7:03 PM
$OTLK I think it is safe to say that we all DAMN WELL KNOW that BP is not allowing the FDA to approve LYT. Perhaps OTLK thought a “Class 1” resubmission would pass muster, as most do. Perhaps other “arrangements” were in play. But we should all be aware of four things now, seemingly without question: 1). BP & their FDA puppets will never allow a disruptor like OTLK to threaten major profit streams. 2). LYT must obviously pose a threat to them. 3). Cencora is evidently NOT going to use its muscle to overpower BP in this case 4). It appears that the only paths foward are: licensing, partnership, buyout, or belly up. Imho.
1 · Reply
FrancX
FrancX Jan. 14 at 7:03 PM
$OTLK OMG is like an horror film…
1 · Reply
Ihuarraqax123
Ihuarraqax123 Jan. 14 at 7:00 PM
$OTLK what a mess ...
0 · Reply
growseed
growseed Jan. 14 at 6:38 PM
0 · Reply
adayxs
adayxs Jan. 14 at 6:10 PM
$OTLK Longs, I believe this will never be approved without BP getting some of it. It will always be another issue, another stall, some other BS. Maybe if the dispute manager thinks we have a case or they hire a law firm to handle it (I sent them one) we have a chance. To just go after more data is a fool's errand.
3 · Reply
thedavidsonny
thedavidsonny Jan. 14 at 6:03 PM
$IVP Price target of $3.X plus!!! Lets push this thing!!! ALL ARE WELCOME AT THE TABLE!!! COME EAT!!!! 💰 🤑 💸 💲 🪙 💶 💰 🤑 💸 💲 $OTLK $PAVS $MTEN
0 · Reply
Consti22
Consti22 Jan. 14 at 5:57 PM
$OTLK I found something in another forum. Sounds perfectly plausible. 😎 “Since Lytenava has only been commercially available in Germany since the fourth quarter of 2025, the first patient cohorts will only reach the crucial 12-week milestone for efficacy measurement in February or March 2026. A Type A meeting in January/February 2026 would simply be too early to present reliable 12-week real-world evidence (RWE) data. At that point, one would only have anecdotal or safety data, but no statistically relevant efficacy curve for week 12. 2. Tactical shift from Type A to Type B By letting the 30-day deadline for the Type A meeting expire, Outlook Therapeutics changes the scenario: Type B meeting: The application could be submitted at the end of January or in February. The FDA then has 60 days to schedule the appointment. The time saved: An application in mid-February would lead to a meeting in April 2026.
4 · Reply
Alder77
Alder77 Jan. 14 at 5:16 PM
$OTLK Declining volumes. Certainly, if the company doesn't communicate anything, at best we'll remain at these levels or just below the absolute minimum, with the serious risk of entering a zombie company phase with no short-term prospects. I still believe they must say something, also because it's implausible to wait for revenue news, which will take months, if not years, to reach an acceptable level. The same goes for potential expansions or partnership or resubmissions to the FDA for the umpteenth time. I really wonder what management intends to do.
0 · Reply
GenerallyGentle
GenerallyGentle Jan. 14 at 5:11 PM
$OTLK this will not move until company makes a move. ie an announcement. Like I said before, I dont expect anything until their upcoming 10q in Feb. If the price starts to climb without news, that is an indication of insider buying pressure from short covering. Because lets face it, this ticker has a pattern of insider knowledge and trading. Cant prove it but the chart shows it before EVERY SINGLE major event.
2 · Reply
Buylocal
Buylocal Jan. 14 at 4:21 PM
$OTLK they got nothing. EU will not buy the product with three strikes by the FDA. Less income than revenue.
2 · Reply
CrazyChief
CrazyChief Jan. 14 at 3:59 PM
$OTLK BP HAS MONEY TO SPEND
0 · Reply
Zestystork
Zestystork Jan. 14 at 3:55 PM
$OTLK What are peoples averages? I’m $1.3 (🫩) down 58% on 356 shares. Is there any point throwing more money at it to av. down or am I better to just close my eyes and think of England? 🫡
7 · Reply
xxtpat
xxtpat Jan. 14 at 3:37 PM
$OTLK An agreement with German health insurance companies will be reached in the foreseeable future. This will result in annual revenues in the double-digit to triple-digit million range. This alone secures Outlook's future. The share price will react by then at the latest.
0 · Reply
SteelerJon
SteelerJon Jan. 14 at 3:21 PM
$OTLK 😎🏦🏦
0 · Reply
Squeeter7
Squeeter7 Jan. 14 at 3:16 PM
$OTLK y’all are dumb
1 · Reply